EPS for TransEnterix, Inc. (TRXC) Expected At $-0.07 on May, 9

April 17, 2018 - By Nellie Rakes

TransEnterix, Inc. (NYSEAMERICAN:TRXC) Corporate Logo
Big Money Sentiment increased to 2.2 in Q4 2017. It has change of 1.29, from 2017Q3’s 0.91. The ratio improved due to TransEnterix, Inc. positioning: 9 sold and 11 reduced. 26 funds amassed stakes and 18 increased stakes. Investors holded 38.42 million in 2017Q3 but now own 50.72 million shares or 32.03% more.
Millennium Mgmt Ltd Liability Corporation has 213,532 shs for 0% of their capital. Geode Mngmt Limited Liability Corporation owns 670,160 shs. Gsa Capital Prns Limited Liability Partnership has 0.07% invested in TransEnterix, Inc. (NYSEAMERICAN:TRXC). Wells Fargo Mn has 0% invested in TransEnterix, Inc. (NYSEAMERICAN:TRXC) for 13,520 shs. Cwm Ltd Co has 0% invested in TransEnterix, Inc. (NYSEAMERICAN:TRXC) for 1,000 shs. Jpmorgan Chase & Com invested 0% of its capital in TransEnterix, Inc. (NYSEAMERICAN:TRXC). D E Shaw & holds 63,180 shs or 0% of its capital. Masters Capital Mgmt Ltd holds 3.88M shs or 0.18% of its capital. The Ontario – Canada-based Royal National Bank & Trust Of Canada has invested 0% in TransEnterix, Inc. (NYSEAMERICAN:TRXC). New York-based Virtu has invested 0.01% in TransEnterix, Inc. (NYSEAMERICAN:TRXC). Ameriprise Inc invested in 0% or 13,376 shs. 2,000 are held by Perigon Wealth Mgmt Ltd. Eam Invsts Limited Co reported 690,784 shs. Stepstone Grp Limited Partnership has 3.03 million shs for 4.08% of their capital. Blackrock owns 1.76 million shs.

Earnings report for TransEnterix, Inc. (NYSEAMERICAN:TRXC) is awaited On May, 9., as reported by RTT. The EPS diference is $0.06 or 46.15 % up from last years number. Previous year: $-0.13; Analysts forcast: $-0.07. Wall Street sees -82.50 % EPS growth as of May, 9. On during the last trading session the stock increased $0.02 or 1.09%, reaching $1.85.Currently TransEnterix, Inc. is uptrending after 34.15% change in last April 17, 2017. TRXC has 1.34M shares volume. TRXC outperformed by 22.60% the S&P500.

TransEnterix, Inc., a medical device company, focuses on the development and commercialization of surgical robotic systems.The firm is valued at $373.65 million. The firm offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.Currently it has negative earnings. It also develops SurgiBot System, a single-port, robotically enhanced laparoscopic surgical platform.

TransEnterix, Inc. (NYSEAMERICAN:TRXC) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.